# Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer

> **NCT01171729** · PHASE1,PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 12 (actual)

## Conditions studied

- Prostatic Cancer

## Interventions

- **BIOLOGICAL:** Autologous dendritic cell

## Key facts

- **NCT ID:** NCT01171729
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2010-08-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01171729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01171729, "Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01171729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*